Research demonstrates that socioeconomic inequalities are "strong determinants" of cardiovascular risk throughout the world.
Members of the writing committee for the American College of Cardiology/American Heart Association 2019 Guideline on Primary Prevention of Cardiovascular Disease incorporated throughout the guideline consideration of how social determinants of health may impact the efficacy of specific guidance and prescriptions for an individual patient. ACC/AHA recommends that clinicians revisit these considerations at each follow-up visit.
Considerations include but are not limited to socioeconomic and educational status as well as cultural, home, and employment environments. The slides below highlight examples of considerations cited by the ACC/AHA for 7 health domains.
Social Determinants of Health and Prevention of Cardiovascular Disease
Research demonstrates that socioeconomic inequalities are "strong determinants" of cardiovascular risk throughout the world.
Members of the writing committee for the American College of Cardiology/American Heart Association 2019 Guideline on Primary Prevention of Cardiovascular Disease incorporated throughout the guideline consideration of how social determinants of health may impact the efficacy of specific guidance and prescriptions for an individual patient. ACC/AHA recommends that clinicians revisit these considerations at each follow-up visit.
Considerations include but are not limited to socioeconomic and educational status as well as cultural, home, and employment environments. The slides below highlight examples of considerations cited by the ACC/AHA for 7 health domains.
Tirzepatide Improves Heart Failure Symptoms and Renal Function in People with Obesity, CKD
ACC 2025. Tirzepatide improved HF symptoms and renal function in patients with obesity-related HFpEF, regardless of CKD status, according to new findings from the SUMMIT trial.
Navigating Cardiovascular Complications of Obesity: Expert Insights for Primary Care
Listen to our latest podcast episode for details on top CVD risk factors to screen patients with obesity for, medications to help prevent CVD, and more.
Dexcom G7 15 Day CGM System Cleared by FDA
The extended wear benefit is augmented by the G7 15 Day CGM system's superior evidence-based accuracy, with a MARD of 8.0%
Obesity & Type 2 Diabetes: An Expert Discussion
In our latest episode, 2 obesity experts discuss the importance of early intervention to reduce risk for complications, suggestions for managing patients in primary care, and more.
Aprocitentan Reduces BP in Black Adults with Resistant Hypertension and Lowers Proteinuria
Aprocitentan, when added to background therapy of at least 3 antihypertensive agents, led to clinically meaningful and sustained BP reduction in this preplanned subanalysis.
Switching to Tirzepatide Outweighs Escalating Dulaglutide Dose in T2D: SURPASS-SWITCH Trial
Breaking research presented at ACP Internal Medicine 2025 showed that switching GLP1-RAs resulted in better glucose and weight control among adults with inadequately controlled T2D.
Tirzepatide Improves Heart Failure Symptoms and Renal Function in People with Obesity, CKD
ACC 2025. Tirzepatide improved HF symptoms and renal function in patients with obesity-related HFpEF, regardless of CKD status, according to new findings from the SUMMIT trial.
Navigating Cardiovascular Complications of Obesity: Expert Insights for Primary Care
Listen to our latest podcast episode for details on top CVD risk factors to screen patients with obesity for, medications to help prevent CVD, and more.
Dexcom G7 15 Day CGM System Cleared by FDA
The extended wear benefit is augmented by the G7 15 Day CGM system's superior evidence-based accuracy, with a MARD of 8.0%
Obesity & Type 2 Diabetes: An Expert Discussion
In our latest episode, 2 obesity experts discuss the importance of early intervention to reduce risk for complications, suggestions for managing patients in primary care, and more.
Aprocitentan Reduces BP in Black Adults with Resistant Hypertension and Lowers Proteinuria
Aprocitentan, when added to background therapy of at least 3 antihypertensive agents, led to clinically meaningful and sustained BP reduction in this preplanned subanalysis.
Switching to Tirzepatide Outweighs Escalating Dulaglutide Dose in T2D: SURPASS-SWITCH Trial
Breaking research presented at ACP Internal Medicine 2025 showed that switching GLP1-RAs resulted in better glucose and weight control among adults with inadequately controlled T2D.